Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model
Introduction. The hepatic steatosis of the nonalcoholic origin or NAFLD is increasing at present, particularly in Western countries, parallel to the increase in obesity, constituting one of the most prevalent hepatic processes in the Western society. Melatonin has been successfully tested in experim...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2020/7315253 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547165318152192 |
|---|---|
| author | Blanca Martínez Soriano Antonio Güemes Guillermo Pola Azucena Gonzalo Pilar Palacios Gasós Ana C. Navarro Roberto Martínez-Beamonte Jesús Osada José J. García |
| author_facet | Blanca Martínez Soriano Antonio Güemes Guillermo Pola Azucena Gonzalo Pilar Palacios Gasós Ana C. Navarro Roberto Martínez-Beamonte Jesús Osada José J. García |
| author_sort | Blanca Martínez Soriano |
| collection | DOAJ |
| description | Introduction. The hepatic steatosis of the nonalcoholic origin or NAFLD is increasing at present, particularly in Western countries, parallel to the increase in obesity, constituting one of the most prevalent hepatic processes in the Western society. Melatonin has been successfully tested in experimental models in mice as a drug capable of reversing steatosis. The effect of melatonin on fat metabolism can be summarized as a decrease in lipid peroxidation and a decrease in oxidative stress, biochemical phenomena intimately related to fat deposition in the hepatocyte. There are hardly any studies in large animals. Objective. In this study, we investigate the effects of melatonin administered orally at a dose of 10 mg/kg/day to reverse established hepatic steatosis induced by a special diet in a porcine animal model. Materials and Methods. We analyze the parameters of oxidative stress: malondialdehyde (MDA), 4-hydroxyalkenals (4-HDA), and carbonyls, degree of fat infiltration (analyzed by direct vision by a pathologist and by means of a computer program of image treatment), and serological parameters of lipid metabolism and hepatic damage. These parameters were analyzed in animals to which hepatic steatosis was induced by means of dietary modifications. Results. We have not been able to demonstrate globally a beneficial effect of melatonin in the improvement or reversal of liver steatosis once established, induced by diet in a porcine animal model. However, we have found several signs of improvement at the histological level, at the level of lipid metabolism, and at the level of oxidative stress parameters. We have verified in our study that, in the histological analysis of the liver sample by means of the program image treatment (free of subjectivity) of the animals that continue with the diet, those that consume melatonin do not increase steatosis as much as those that do not consume it significantly (p=0.002). Regarding the parameters of oxidative stress, MDA modifies in a significant manner within the group of animals that continue with the diet and take melatonin (p=0.004). As for lipid metabolism, animals that maintain the steatotic diet and take melatonin lower total and LDL cholesterol levels and increase HDL levels, although these results do not acquire statistical significance. Conclusions. In this study, it has not been possible to demonstrate a beneficial effect of melatonin in the improvement or reversal of liver steatosis once established and induced by diet in the porcine model. It is true that signs of improvement have been found at the histological level, at the level of lipid metabolism, and at the level of oxidative stress phenomena, when comparing animals with established steatosis that are treated with melatonin with those who do not take it. This work is the first study conducted in a large animal model in which the effect of melatonin is studied as a treatment in the reversal of established hepatic steatosis. |
| format | Article |
| id | doaj-art-993a8517585e46499563550a2e4072ca |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-993a8517585e46499563550a2e4072ca2025-02-03T06:45:53ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972020-01-01202010.1155/2020/73152537315253Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental ModelBlanca Martínez Soriano0Antonio Güemes1Guillermo Pola2Azucena Gonzalo3Pilar Palacios Gasós4Ana C. Navarro5Roberto Martínez-Beamonte6Jesús Osada7José J. García8Department of Surgery, University Hospital Lozano Blesa, Zaragoza, SpainDepartment of Surgery, University Hospital Lozano Blesa, Zaragoza, SpainDepartment of Surgery, General Defense Hospital, Zaragoza, SpainDepartment of Surgery, University Hospital Lozano Blesa, Zaragoza, SpainDepartment of Surgery, University Hospital Lozano Blesa, Zaragoza, SpainDepartment of Surgery, University Hospital Lozano Blesa, Zaragoza, SpainCIBER (Biomedical Net Investigation Centre), Obesity and Nutrition Physiopathology, Madrid, SpainDepartment of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, Zaragoza, SpainDepartment of Physiology, University of Zaragoza, Zaragoza, SpainIntroduction. The hepatic steatosis of the nonalcoholic origin or NAFLD is increasing at present, particularly in Western countries, parallel to the increase in obesity, constituting one of the most prevalent hepatic processes in the Western society. Melatonin has been successfully tested in experimental models in mice as a drug capable of reversing steatosis. The effect of melatonin on fat metabolism can be summarized as a decrease in lipid peroxidation and a decrease in oxidative stress, biochemical phenomena intimately related to fat deposition in the hepatocyte. There are hardly any studies in large animals. Objective. In this study, we investigate the effects of melatonin administered orally at a dose of 10 mg/kg/day to reverse established hepatic steatosis induced by a special diet in a porcine animal model. Materials and Methods. We analyze the parameters of oxidative stress: malondialdehyde (MDA), 4-hydroxyalkenals (4-HDA), and carbonyls, degree of fat infiltration (analyzed by direct vision by a pathologist and by means of a computer program of image treatment), and serological parameters of lipid metabolism and hepatic damage. These parameters were analyzed in animals to which hepatic steatosis was induced by means of dietary modifications. Results. We have not been able to demonstrate globally a beneficial effect of melatonin in the improvement or reversal of liver steatosis once established, induced by diet in a porcine animal model. However, we have found several signs of improvement at the histological level, at the level of lipid metabolism, and at the level of oxidative stress parameters. We have verified in our study that, in the histological analysis of the liver sample by means of the program image treatment (free of subjectivity) of the animals that continue with the diet, those that consume melatonin do not increase steatosis as much as those that do not consume it significantly (p=0.002). Regarding the parameters of oxidative stress, MDA modifies in a significant manner within the group of animals that continue with the diet and take melatonin (p=0.004). As for lipid metabolism, animals that maintain the steatotic diet and take melatonin lower total and LDL cholesterol levels and increase HDL levels, although these results do not acquire statistical significance. Conclusions. In this study, it has not been possible to demonstrate a beneficial effect of melatonin in the improvement or reversal of liver steatosis once established and induced by diet in the porcine model. It is true that signs of improvement have been found at the histological level, at the level of lipid metabolism, and at the level of oxidative stress phenomena, when comparing animals with established steatosis that are treated with melatonin with those who do not take it. This work is the first study conducted in a large animal model in which the effect of melatonin is studied as a treatment in the reversal of established hepatic steatosis.http://dx.doi.org/10.1155/2020/7315253 |
| spellingShingle | Blanca Martínez Soriano Antonio Güemes Guillermo Pola Azucena Gonzalo Pilar Palacios Gasós Ana C. Navarro Roberto Martínez-Beamonte Jesús Osada José J. García Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model Canadian Journal of Gastroenterology and Hepatology |
| title | Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model |
| title_full | Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model |
| title_fullStr | Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model |
| title_full_unstemmed | Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model |
| title_short | Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model |
| title_sort | effect of melatonin as an antioxidant drug to reverse hepatic steatosis experimental model |
| url | http://dx.doi.org/10.1155/2020/7315253 |
| work_keys_str_mv | AT blancamartinezsoriano effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel AT antonioguemes effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel AT guillermopola effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel AT azucenagonzalo effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel AT pilarpalaciosgasos effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel AT anacnavarro effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel AT robertomartinezbeamonte effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel AT jesusosada effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel AT josejgarcia effectofmelatoninasanantioxidantdrugtoreversehepaticsteatosisexperimentalmodel |